ReShape Lifesciences Files Definitive Proxy Statement
Ticker: HIND · Form: DEF 14A · Filed: Mar 14, 2025 · CIK: 1427570
| Field | Detail |
|---|---|
| Company | Reshape Lifesciences Inc. (HIND) |
| Form Type | DEF 14A |
| Filed Date | Mar 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
ReShape Lifesciences filed its proxy statement for the shareholder meeting. Vote on company matters.
AI Summary
ReShape Lifesciences Inc. filed its definitive proxy statement on March 14, 2025, for its annual meeting of stockholders. The filing, under the SEC Act of 1934, concerns the company's corporate governance and matters to be voted on by shareholders. ReShape Lifesciences Inc. is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides shareholders with crucial information regarding the company's leadership, executive compensation, and proposals requiring their vote, impacting the direction and governance of ReShape Lifesciences Inc.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) that provides information to shareholders and does not inherently introduce new risks.
Key Players & Entities
- ReShape Lifesciences Inc. (company) — Registrant
- 0001104659-25-023989 (filing_id) — Accession Number
- 20250314 (date) — Filing Date
- 20250401 (date) — Period of Report
- 001-37897 (filing_id) — SEC File Number
- 1001 CALLE AMANECER, SAN CLEMENTE, CA 92673 (address) — Business and Mail Address
- Obalon Therapeutics Inc. (company) — Former Company Name
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a definitive proxy statement, is filed by a company to provide shareholders with information they need to vote on matters at an upcoming shareholder meeting, such as the election of directors and executive compensation.
When was this definitive proxy statement filed by ReShape Lifesciences Inc.?
ReShape Lifesciences Inc. filed this definitive proxy statement on March 14, 2025.
What is the fiscal year end for ReShape Lifesciences Inc.?
The fiscal year end for ReShape Lifesciences Inc. is December 31 (1231).
What was ReShape Lifesciences Inc. formerly known as?
ReShape Lifesciences Inc. was formerly known as Obalon Therapeutics Inc., with a date of name change on February 20, 2008.
What is the primary business classification for ReShape Lifesciences Inc.?
ReShape Lifesciences Inc. is classified under Pharmaceutical Preparations [2834] according to its Standard Industrial Classification.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 14, 2025 regarding ReShape Lifesciences Inc. (HIND).